FUND I
Driving innovation in healthcare through our investment principles grounded in an evidence-based, collaborative diligence process
Along with 1 HIP VC Members
Along with 3 HIP VC Members
Along with 2 HIP VC Members
Along with 2 HIP VC Members
Along with 3 HIP VC Members
Along with 1 HIP VC Members
Fund I is fully committed
Schedule a 15-minute call to learn about additional investment opportunities
Our Investment Thesis
| Supporting the Right Unmet Needs While Fueling Much Needed Growth |
The HIP Fund I is strategic capital from experienced healthcare LPs focused on supporting technology-based solutions that positively impact healthcare
Health Technology
Data and AI solutions centered around better decision-making and efficiency
Consumer Health
Providing consumers affordable options while improving access and healthcare spend
Health IT
Opportunistic solutions helping reduce the cost of delivering care across healthcare institutions
Digital Health
Modernizing traditional manual aspects of accessing care, related services and supporting initiatives such as improving health equity and cost of care
Life Sciences
Hardware and software across precision medicine, diagnostics and medical devices focusing on reducing cost of care and improving efficiency and outcomes
Women's Health
Traditionally under innovated and funded area where an abundance of opportunity exists to improve access to care, and increase clinical quality of innovations
CRITERIA
WHAT WE DON’T INVEST IN
What Makes Us Unique
| Control Risk + Focus on Creating Value and Returns |
An investment plan based on an evidence-based diligence process backed by top healthcare experts to manage risk while focusing on creating value and returns
STRATEGY
Diversified multidisciplinary collaborative ecosystem that mitigates risk and commercializes effective healthcare innovations
⎻ Collaborative ecosystem of 200+ investors
⎻ Sourcing of opportunities – 80% of pipeline comes from HIP investor network – pre-vetted deal flow
⎻ Multidisciplinary expert-led diligence – every voice counted
MODEL
Multi-angle deployment with value-add impact built-in
⎻ Unique LP-friendly fund structure
⎻ Opportunity to participate in sidecar SPVs including growth stage investments through strategic VC partners
⎻ Attaining investor rights and pro-rata in each investment as an early-stage investor
⎻ Syndicate opportunity with value-add VCs and Strategic Investors
DECISION MAKING
Early-stage investing with the most complete risk mitigation process
⎻ Multifaceted validation covering every angle (i.e. clinical, product/technology, commercialization, people/leadership)
⎻ Proprietary investing platform providing transparency on diligence and decision making to all investors
⎻ Shared decision-making based on evidence-based construct
EXECUTION
Smart capital deployment thesis ensuring early risk detection, growth, and returns
⎻ Required post-investment advisory model enforces return on investment
⎻ Hands-on approach to manage future capital raises for investments
⎻ Large strategic network used to drive revenue grow and profitability
⎻ Provide investors an opportunity to participate with portfolio companies (i.e. clinical, product development, BD)
Deal Flow
| From Opportunity to Investment |
In addition to providing relevant expertise through the diligence process, HIP investors also offer invaluable advisory support post-investment to assist company growth and scale
600
Annual Deals in Pipeline
80
Annual Deals from Accelerators
70/20/10
Ratio of Seed or Seed Extension / Series A / Series B
50/50
Ratio of Follow-on Investments in Existing Portfolio / New Deals
4 Months
Average Time Spent in Diligence Before Investment
Stage and Check Size
Stage: Seed through Series A. Future plans for reserve funds for follow on. Post-investment agreement executed with value-add investors established as advisors for portfolio company.
Initial Check size: $150K-$250K
Traction:
MVP with some semblance of adoption (i.e. users, revenue, date), life sciences: no earlier than 12-18 months pre FDA approval.
Deal Sourcing
| Extensive Sourcing Through Value-Add Industry Partners |
Robust healthcare-only HIP Investor Network has over 80 institutional investors including 16 US health systems – yielding over 60% of our pipeline
PARTNERSHIPS THAT SPAN THE INDUSTRY
Relationships with the largest and most reputable accelerators, incubators and professional healthcare organizations globally. Here's a small sampling:
HEALTHCARE KOL’S AND SME’S WITH 1800+ YEARS OF EXPERIENCE
The HIP Investor Network also includes over 120 non-institutional investors who are healthcare industry executives, entrepreneurs and clinicians. Their active support results in over 25% of our pipeline. Here's a small sampling:
HIP Institutional Investors and Co-Investors
Focused and purposeful collaborative ecosystem gives us an unmatched ability to not only co-invest but also leverage our partners in diligence and decision-making.
Fund I is fully committed
Schedule a 15-minute call to learn about additional investment opportunities
The current approach to healthcare investing is broken
We are on a mission to change that!
Traditional ways of investing do not work in healthcare. A collaborative approach that brings all stakeholders of a healthcare startup’s journey need to be at the table to make an informed and successful investment decision. HIP is shattering the status quo by bringing together financial (angel, family office, VC, PE) and strategic investors (payers, providers, delivery systems) into the analysis, due diligence, and advisory roles of our portfolio companies.
Managing Partner & Founder, HIP
Testimonials
Dr. Hetal Bhakta
cardiologist
HIP venture fund employs a collaborative diligence process that rigorously validates clinical efficacy and viability into existing workflows by practicing clinical experts. I feel confident that the innovations backed by HIP enhance patient care, support healthcare professionals in delivering the best outcomes while ensuring investor returns.
Jeff Zucker
experienced healthcare entrepreneur
HIP is the first entity to bring often-competitive stakeholders (healthcare related consumer, business and government vectors) into one coordinated discussion mitigating risk by speeding paths to market and scale. Just as “coordinated care” tries to improve clinical performance by forcing specialists to share information, brainstorm and focus, HIP’s first-ever“coordinated financing” model is our best hope of helping amazing entrepreneurs to turn their ideas into reality.
Steve Grau
experienced healthcare entrepreneur
As a seasoned healthcare operator and leader, I highly value my investment in HIP. The due diligence process at HIP is exemplary, bringing together knowledgeable, resourceful, and experienced investors who deeply care about healthcare innovation. This collaborative approach ensures thorough, collective investment decisions, providing startups with robust support and guidance. HIP stands out for its ability to advance healthcare innovation through strategic capital and a nurturing ecosystem.
Susan Solinsky
experienced women's health entrepreneur
HIP stands out as a stellar health tech fund for several compelling reasons. As an LP, I’ve been continually impressed by the fund’s robust investment thesis, which is meticulously crafted and forward-thinking. The management team’s profound understanding of the healthcare sector ensures that every investment is strategically sound and impactful. Furthermore, from a founder’s perspective, the support and collaboration of the fund post-investment around GTM and team building is unparalleled. HIP is a true partner dedicated to the success and innovation of its portfolio companies, which I expect to generate best-in-class returns
Christine Brocato
health system innovation executive
HIP excels as a robust healthcare focused fund due to the assembly of passionate healthcare leaders from various medical and business fields. I value that innovations are sourced from across the ecosystem with a focus on experienced founders developing meaningful solutions to pressing healthcare challenges, and diligence is informed by practicing clinicians, operators and seasoned investors.
Dr. Barry Rosen
breast surgeon
As a breast surgeon and supporter of cutting edge healthcare innovation, I'm thrilled to invest in a healthcare venture fund that employs a collaborative diligence process emphasizing clinical efficacy and workflow. The HIP thesis is uniquely supported by a multidisciplinary ecosystem of investors, including physicians, entrepreneurs, venture capital firms, technologists, health systems, payors, and other key players from the healthcare industry. The fund’s commitment to providing strategic advisory support to portfolio companies ensures that innovations are not only groundbreaking but also practically integrated into clinical settings, ultimately improving patient outcomes and supporting positive returns.
faq
Follow-on investments vary and depend on the performance of the portfolio company as it scales and progresses to Series A or beyond.
We are managed out of Silicon Valley, California. However, our active LPs are based all over the country, including Los Angeles, Austin, Dallas, New York City, and Boston.
At this stage, we are highly knowledgeable about the US healthcare market, with a concentration on startups based in the US. However, we will consider investments in opportunities that are expanding into global markets or global startups that have significant growth overseas and initial traction in the US. This US-based strategy also conveniently applies to Canada.
Absolutely, we structure and manage sidecar investments for every opportunity we invest in through the fund. This allows our LPs and HIP network members to increase their investments in opportunities they find appealing.
Our LPs are dedicated healthcare experts with a deep passion and extensive knowledge of the industry. This is the true differentiator of the HIP Fund model. Our LP base includes healthcare executives, portfolio company founders, venture capitalists, physicians, and entrepreneurs. All of our LPs are required members of the HIP network and are provided opportunities to serve as active advisors to our portfolio companies.
HIP utilizes an evidence-based collaborative investment model, designed and created by HIP. This process, grounded in a diligence-first approach, provides an appropriate risk aversion strategy through the involvement of over 250 healthcare investors who offer deep expertise at every step of the investment decision process.
Our collaborative ecosystem is what makes HIP impactful and different. We support our portfolio companies with advisory services from a network of Subject Matter Experts (SMEs) and Key Opinion Leaders (KOLs) to help our investments grow. Additionally, we function similarly to a venture studio or accelerator. Our affiliate partners provide essential resources and access to services that startups need to fully execute their business strategies. These affiliate partners include law firms, banks, accounting firms, technology and product development shops, marketing firms, recruiting firms, and much more.
We invite startups to connect and apply through the startup sign-up page.
We are fairly open to lead or co-lead. Regardless of position we take, we take a syndication approach and partner with our startups to help them raise capital through our expansive HIP investor network.
This is not a requirement at this stage. Based on the stage and our position in the capital raise, we may require a board seat or a board observer position.
Absolutely - we love to and prefer to syndicate our investment with and through our HIP investor network.
HIP Fund 1 minimum contribution is $50,000.
We believe in investing in our portfolio companies beyond just providing capital. Our smart capital investing approach requires portfolio companies to agree to post-investment advisory agreements. These agreements establish a clearly defined Statement of Work (SOW) and ensure the delivery of appropriate advisory services by HIP investors in our network. Our investors use their expertise to serve as advisors. The areas we cover include, but are not limited to, medical advisory boards, product expertise, and commercial growth (including leveraging key strategic customer relationships that are part of the HIP network).
HIP is fundamentally focused on multiple elements that set it apart from others. We emphasize a healthcare-first, evidence-based investment decision process through the creation of the HIP Inclusive Investor Network. Our post-investment advisory services are not just talk—we deploy appropriate advisors (who are also investors) to address the portfolio company's needs and drive growth, valuation, and returns. We understand that raising capital is a challenging task for founders, so we partner with them to take over the capital raise strategy. We build and manage real-time portfolio and data rooms on behalf of our investments, making future raises more manageable.
Fund I is fully committed
Schedule a 15-minute call to learn about additional investment opportunities
Disclaimer
The contents of this website are provided for general information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security of HIP Fund I or its affiliates in any jurisdiction. HIP Fund I does not intend to solicit and is not soliciting, any action with respect to any Security or any other contractual relationship. Nothing on this website or the contents thereof, individually or taken in the aggregate, constitutes an offer of securities for sale or a solicitation of an offer to buy any security in the United States or in any other jurisdiction in which such an offer or solicitation is unlawful. HIP Fund I does not make investment recommendations and no communication, through this website or in any other information materials, should be construed as a recommendation for any security. Nothing on this website is intended to constitute legal, tax, securities or investment advice, or opinion regarding the appropriateness of any investment.
This website has been provided to you with the expressed understanding that information contained herein, or made available in connection with any further investigation, is strictly confidential and is intended for your exclusive use. Your receipt of this information is your acknowledgment and agreement that this website and the information contained herein will be maintained in strict confidence and will not be disclosed by you to any third party without the expressed written consent of the Fund. This website and the information contained herein may be disclosed only to your employees, consultants and agents who need to know such information to evaluate an investment in the Fund. Neither this website nor any information contained herein shall be photocopied or reproduced at any time.
Statements on this website describing the Funds’ objectives, projections, estimates, expectations or predictions may be “forward-looking statements” within the meaning of the applicable securities laws and regulations. Such statements are based on beliefs, assumptions, data, and other information currently available to us. Actual results could differ materially from those expressed or implied on this website.
Any investment in the Fund is only intended for accredited investors and qualified investment entities. Investments in early-stage ventures are speculative in nature and involve a high degree of risk. Those investors who cannot afford to lose their entire investment should not invest in such projects. There is no guarantee that the stated project valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive restricted ownership that may be subject to holding period requirements. Early-stage investments should only be part of your overall private investment portfolio. Investors who cannot hold an investment for at least 5 years should not invest.
The information contained herein is subject to change without notice.